Clinical Outcomes in Advanced Non-Small Cell Lung Cancer

The clinical management of advanced non-small cell lung cancer (NSCLC) has advanced markedly over the past decade, shifting from uniform platinum-based chemotherapy to precision approaches guided by molecular profiling and immunology. Outcomes are primarily assessed by overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). Traditional chemotherapy yielded median OS of less than one year, whereas targeted therapies against EGFR and ALK alterations have extended median survival to two years or more in selected cohorts. The advent of immune checkpoint inhibitors has produced durable remissions in a subset of patients, with a plateau in long-term survivors emerging at two to three years. Nevertheless, response heterogeneity and acquired resistance remain critical obstacles. The validity of surrogate endpoints such as PFS and ORR varies with treatment modality, and trial populations often differ from routine practice. Integration of real-world data and computational methods aims to refine prognostic models, optimise trial design and improve individualised care. Globally, NSCLC remains a leading cause of cancer mortality, and continued efforts focus on combination regimens, novel targets and sequencing strategies to enhance survival and quality of life.

Research from Nature Portfolio

Recent studies have used machine-learning frameworks to evaluate how well randomised controlled trial outcomes translate into routine clinical settings. One investigation developed an emulation platform that stratified patients into prognostic risk groups based on electronic health records and then compared real-world survival benefits of standard regimens with those reported in landmark trials. Results showed close alignment in low- and medium-risk groups but substantially lower survival in high-risk phenotypes, highlighting the influence of patient heterogeneity on trial generalisability and underscoring the role of data-driven tools in guiding individual treatment decisions and trial design.

Clinical Outcomes in Advanced Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in clinical outcomes in advanced non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival (OS): Time from treatment initiation to death from any cause.

Progression-free survival (PFS): Time from treatment start to objective disease progression or death.

Objective response rate (ORR): Proportion of patients achieving a predefined reduction in tumour burden.

Real-world data (RWD): Information on patient health and treatment collected outside controlled trials, such as electronic health records.

Surrogate endpoint: An indirect measure, for example PFS, used to predict direct clinical benefit like survival.

References

1. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nature Medicine (2025).
2. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Medicine (2021).
3. Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data. Clinical Cancer Research (2022).
4. Overview of approaches to estimate real-world disease progression in lung cancer. JNCI Cancer Spectrum (2023).